Indoco Remedies Ltd
Indoco Remedies (Indoco) is a Mumbai-based pharmaceutical company that focuses on formulations with a presence in contract manufacturing and research. The Company is engaged in the manufacturing and marketing of pharmaceutical Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).[1]
- Market Cap ₹ 3,056 Cr.
- Current Price ₹ 332
- High / Low ₹ 424 / 306
- Stock P/E 21.6
- Book Value ₹ 111
- Dividend Yield 0.45 %
- ROCE 17.2 %
- ROE 14.6 %
- Face Value ₹ 2.00
Pros
- Company has delivered good profit growth of 28.7% CAGR over last 5 years
Cons
- The company has delivered a poor sales growth of 9.93% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
568 | 629 | 726 | 851 | 1,005 | 1,072 | 1,038 | 968 | 1,106 | 1,240 | 1,540 | 1,667 | |
483 | 536 | 606 | 686 | 834 | 915 | 903 | 891 | 982 | 1,016 | 1,212 | 1,382 | |
Operating Profit | 85 | 93 | 120 | 165 | 171 | 157 | 135 | 77 | 124 | 224 | 328 | 285 |
OPM % | 15% | 15% | 17% | 19% | 17% | 15% | 13% | 8% | 11% | 18% | 21% | 17% |
2 | 1 | 2 | 2 | 1 | 4 | 5 | 6 | 2 | 3 | 2 | 2 | |
Interest | 16 | 22 | 19 | 10 | 12 | 6 | 24 | 21 | 26 | 22 | 14 | 25 |
Depreciation | 19 | 24 | 31 | 47 | 61 | 63 | 68 | 72 | 71 | 73 | 79 | 71 |
Profit before tax | 51 | 48 | 72 | 109 | 99 | 91 | 48 | -9 | 29 | 131 | 236 | 192 |
Tax % | 10% | 12% | 20% | 24% | 17% | 15% | 15% | 69% | 16% | 30% | 35% | 26% |
Net Profit | 46 | 43 | 58 | 83 | 82 | 77 | 41 | -3 | 24 | 92 | 155 | 141 |
EPS in Rs | 5.04 | 4.63 | 6.28 | 8.99 | 8.93 | 8.41 | 4.47 | -0.31 | 2.63 | 10.03 | 16.77 | 15.34 |
Dividend Payout % | 15% | 24% | 22% | 18% | 18% | 19% | 22% | -97% | 11% | 15% | 13% | 15% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 10% |
3 Years: | 15% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 29% |
3 Years: | 80% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | 18% |
5 Years: | 12% |
3 Years: | 14% |
1 Year: | -12% |
Return on Equity | |
---|---|
10 Years: | 11% |
5 Years: | 11% |
3 Years: | 15% |
Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | |
Reserves | 368 | 396 | 439 | 500 | 558 | 633 | 657 | 643 | 662 | 750 | 886 | 1,009 |
114 | 118 | 91 | 94 | 139 | 280 | 282 | 296 | 262 | 267 | 257 | 333 | |
157 | 157 | 178 | 229 | 224 | 266 | 280 | 301 | 330 | 281 | 327 | 300 | |
Total Liabilities | 652 | 689 | 726 | 842 | 939 | 1,197 | 1,238 | 1,258 | 1,272 | 1,317 | 1,488 | 1,660 |
302 | 321 | 325 | 339 | 373 | 440 | 489 | 468 | 590 | 570 | 555 | 720 | |
CWIP | 33 | 38 | 44 | 63 | 55 | 91 | 136 | 185 | 51 | 68 | 122 | 54 |
Investments | 0 | 0 | 0 | 1 | 18 | 3 | 3 | 2 | 2 | 2 | 2 | 20 |
317 | 330 | 356 | 439 | 493 | 664 | 611 | 603 | 630 | 676 | 809 | 866 | |
Total Assets | 652 | 689 | 726 | 842 | 939 | 1,197 | 1,238 | 1,258 | 1,272 | 1,317 | 1,488 | 1,660 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
59 | 69 | 100 | 110 | 112 | 88 | 123 | 132 | 123 | 82 | 174 | 176 | |
-64 | -43 | -41 | -88 | -113 | -171 | -135 | -104 | -56 | -67 | -121 | -205 | |
-7 | -26 | -58 | -21 | 0 | 132 | -39 | -16 | -64 | -30 | -44 | 23 | |
Net Cash Flow | -12 | -0 | 1 | 1 | -0 | 50 | -51 | 12 | 3 | -14 | 8 | -7 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 73 | 74 | 69 | 66 | 68 | 73 | 73 | 73 | 69 | 69 | 70 | 77 |
Inventory Days | 152 | 129 | 147 | 179 | 173 | 188 | 204 | 209 | 230 | 245 | 248 | 228 |
Days Payable | 114 | 95 | 94 | 145 | 137 | 167 | 158 | 195 | 184 | 119 | 108 | 89 |
Cash Conversion Cycle | 111 | 108 | 122 | 100 | 103 | 95 | 119 | 88 | 115 | 195 | 210 | 217 |
Working Capital Days | 71 | 74 | 73 | 77 | 79 | 80 | 77 | 64 | 56 | 107 | 113 | 119 |
ROCE % | 14% | 14% | 17% | 21% | 17% | 12% | 7% | 1% | 6% | 16% | 23% | 17% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
48m - The Board of the Directors of the Company at their meeting held on June 5, 2023, approved the acquisition of 85% equity stake in FPP …
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
46m - The Board of the Directors of the Company at their meeting held on June 5, 2023, approved the acquisition of 85% equity stake in FPP …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
43m - The Board of the Directors of the Company at their meeting held on June 5, 2023, approved the acquisition of 85% equity stake in FPP …
- Indoco Remedies Limited Clinical Research Organisation (CRO), Anacipher, Receives Clearance On Remote Record Assessment From USFDA 1d
- Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Indoco Remedies Limited Goa Plant II- Classified With OAI Status 2d
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
May 2023TranscriptPPT
-
Jan 2023TranscriptPPT
-
Nov 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Nov 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Nov 2020TranscriptPPT
-
Aug 2020TranscriptPPT
-
Jun 2020TranscriptPPT
-
Jan 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Jan 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Aug 2018TranscriptPPT
Business segments
A) Domestic Formulations (41% of FY22 revenue)[1] Company offers high-quality medicines in multiple therapeutic categories, which include diabetology, respiratory, stomatology, women's health, nutritional products, gastroenterology, cardiology, metabolic disorders, and primary care medicines.
The Company has a predominant presence in the South (37%) and West (33%), followed by the East (17%) and North (12%). The Company caters to multiple doctor specialties and generates more than 83 million prescriptions annually from over 3,00,000 doctors across India